Mark J. Fitzpatrick brings to Proteon more than 17 years experience in the financial management of biotechnology companies, including as Chief Financial Officer of RenaMed Biologics, Inc. and Dynogen Pharmaceuticals, Inc., both privately held companies, as well as Diacrin, Inc., where he successfully completed its IPO. He also held financial management positions at Repligen Corporation and served on the professional staff of Arthur Andersen and Co.
About Proteon Therapeutics
Proteon Therapeutics, Inc. is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical, rapidly expanding medical needs of patients with renal and vascular diseases. The company is leveraging a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics. The company is headquartered in Waltham, MA and has research facilities in Kansas City, MO. For additional information please visit http://www.proteontherapeutics.com.
|SOURCE Proteon Therapeutics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved